At North Louisiana Orthopaedic & Sports Medicine Clinic, we are dedicated to offering the latest and most advanced treatments and procedures to get you back to doing what you love. That’s why we offer regenerative medicine therapy, including BioDFactor® Viable Tissue Matrix, as a nonsurgical treatment option for soft-tissue injuries and chronic conditions.

What Is BioDFactor?

BioDFactor is a human placental tissue allograft processed using proprietary technology. Human placental tissues have been shown clinically and scientifically to support soft-tissue repair.¹ BioDFactor is derived from tissues acquired from living, healthy donors after a full-term pregnancy and a scheduled cesarean section. These tissues have been minimally processed and preserved to maintain the properties of the placental tissues.

This product is only available through a physician or licensed healthcare provider.

What Is an Allograft?

An allograft is tissue from a human donor that is transplanted from one body to another.

Why Human Placental Tissues?

Clinicians have used human placental tissues for over a century as a biologic dressing in a broad range of therapeutic applications.² They have been generally recognized as versatile wound coverings, with published clinical results cited extensively in the literature.³ Human placental tissues are an abundant source of collagen, as well as other proteins and cytokines. Human placental tissues are “immune-privileged” and therefore rarely cause an immune response in the human body.⁴

Safety & Quality Are Our Highest Priorities.

BioD is committed to the safety of our patients and the quality of our products. BioD products are processed in accordance with all applicable industry standards and regulations, including those set forth by the Food and Drug Administration (FDA) and the American Association of Tissue Banks (AATB), for human cellular and tissue-based products. Our processes have been developed to preserve the placental tissues’ characteristics, including the extracellular matrix and cytokines, with a view to providing clinically beneficial products that benefit patients.

BioDFactor is derived from human placental tissues obtained from living, healthy, and consenting mothers that are prescreened during pregnancy and selected based on our stringent donor suitability criteria.

Are There Risks Associated With the Use of BioDFactor?

BioDFactor is an allograft that contains tissues derived from a living, healthy donor. As with the implantation of any human tissue, there is always the possibility of an allergic reaction or transmission of a communicable disease in connection with the use of this product.

Consult with your healthcare provider regarding adverse reactions or any questions you may have regarding the use of this product.

Applications

BioDFactor is a placental-derived allograft used as a wound covering in the treatment of localized tissue voids and defects.

Your physician can determine if your medical condition is appropriate for treatment with BioDFactor and if so, will advise you as to the recommended treatment based on their professional assessment of your condition.

BioD’s Commitment to Regenerative Science

BioDFactor is processed and distributed by BioDLogics, LLC, a company engaged in the development of advanced biologic products derived from human placental tissues obtained following caesarian births. Our research and development efforts are focused on the regenerative potential of birth tissues, given their unique biologic characteristics.

We believe the use of living, healthy donors is a better approach to regenerative medicine.

To learn more about the regenerative medicine therapy we offer or to schedule an appointment, please call (318) 362-4411 or request an appointment online.

References:

• 1. Niknejad, H, et al. Properties of placental membrane for potential use in Tissue Engineering. European Cells and Materials 2008; Vol. 15: 88–99.
• 2. Davis JW. Skin Transplantation. Johns Hopkins Med J; 1910;15:307–96.
• 3. https://www.ncbi.nlm.nih.gov/pubmed/?term=human-amnion+allograft
• 4. Kubo, et al. Immunogenicity of Human Placental Membrane in Experimental Xenotransplantation. Investigative Ophthalmology & Visual Science, June 2001, Vol. 42, No. 7.